This interview was recorded live on Zoom with an audience of NET cancer patients and caregivers.

In part 2 of the interview, Dr. Chauhan continues his discussion of issues that impact NET patients and answers live questions directly from patients.

Dr. Aman Chauhan is board certified in internal medicine and specializes in the treatment of neuroendocrine tumors. He is a member of the medical oncology team at the UK Markey Cancer Center dedicated to multidisciplinary evaluation and treatment.

His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and non-small cell lung cancer. As Markey’s director of NET Theranostics, Dr. Chauhan will identify NET patients who qualify for Lutathera® (Lutetium 177 DOTATATE) treatments for gastroenteropancreatic neuroendocrine tumors.

In this episode, Dr. Chauhan discusses many issues that impact NET patients, including COVID-19.

Dr. Aman Chauhan is board certified in internal medicine and specializes in the treatment of neuroendocrine tumors. He is a member of the medical oncology team at the UK Markey Cancer Center dedicated to multidisciplinary evaluation and treatment.

His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and non-small cell lung cancer. As Markey’s director of NET Theranostics, Dr. Chauhan will identify NET patients who qualify for Lutathera® (Lutetium 177 DOTATATE) treatments for gastroenteropancreatic neuroendocrine tumors.

Dr. Eric Liu is an internationally-recognized neuroendocrine tumor surgeon with the Rocky Mountain Cancer Centers in Denver, Colorado.

Dr. Joseph Dillon, an endocrinologist and neuroendocrine cancer expert, is part of the faculty at the University of Iowa Holden Comprehensive Cancer Center, a Center of Excellence for the treatment of NETs. In this show he will be answering some critical questions regarding how neuroendocrine cancer patients can receive the best care possible.